Trastuzumab Active Not Recruiting Phase 2 Trials for Cancer, Breast / Brain Tumor - Metastatic Treatment

Back to Trastuzumab

Indications	Status	Purpose	Phase
DBCOND0054116 (Cancer, Breast) DBCOND0073320 (Brain Tumor - Metastatic)	Active Not Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT01491737	A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer	Trastuzumab (DB00072) Pertuzumab (DB06366)
NCT00003612	Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer	Paclitaxel (DB01229) Carboplatin (DB00958) Trastuzumab (DB00072)
NCT02132949	A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer	Trastuzumab (DB00072) Epirubicin (DB00445) Cyclophosphamide (DB00531) Doxorubicin (DB00997) Paclitaxel (DB01229) Docetaxel (DB01248) Fluorouracil (DB00544) Pertuzumab (DB06366)
NCT00796978	Trastuzumab in Treating Older Women With Early-Stage Breast Cancer	Trastuzumab (DB00072)
NCT00470704	Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer	Trastuzumab (DB00072) Lapatinib (DB01259)
NCT00295893	Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer	Carboplatin (DB00958) Trastuzumab (DB00072) Docetaxel (DB01248) Cyclophosphamide (DB00531) Paclitaxel (DB01229) Doxorubicin (DB00997)
NCT01796197	Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa	Paclitaxel (DB01229) Pertuzumab (DB06366) Cyclophosphamide (DB00531) Doxorubicin (DB00997) Trastuzumab (DB00072)
NCT01853748	T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)	Trastuzumab emtansine (DB05773) Paclitaxel (DB01229) Trastuzumab (DB00072)
NCT02260531	Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases	Cabozantinib (DB08875) Trastuzumab (DB00072)
NCT02073487	Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel	Paclitaxel (DB01229) Lapatinib (DB01259) Trastuzumab (DB00072) Trastuzumab emtansine (DB05773) Pertuzumab (DB06366)
NCT00820872	Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer	Trastuzumab (DB00072) Docetaxel (DB01248) Carboplatin (DB00958) Lapatinib (DB01259)
NCT00254592	Neoadjuvant Treatment of Breast Cancer	Sargramostim (DB00020) Alendronic acid (DB00630) Paclitaxel (DB01229) Bevacizumab (DB00112) Trastuzumab (DB00072) Doxorubicin (DB00997) Carboplatin (DB00958) Cyclophosphamide (DB00531)
NCT01625429	Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer	Trastuzumab (DB00072) Paclitaxel (DB01229)
NCT01745965	A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.	Trastuzumab emtansine (DB05773) Trastuzumab (DB00072)
NCT00999804	Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy	Lapatinib (DB01259) Letrozole (DB01006) Trastuzumab (DB00072)
NCT00971737	Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer	Trastuzumab (DB00072) Cyclophosphamide (DB00531)